title: [Clinical characteristics of acute myeloid leukemia with t (16;21) (p11;q22):nine cases report and literature review].
abstract: OBJECTIVE
  To analyze the biological and clinical characteristics of acute myeloid leukemia (AML) with t (16;21) (p11;q22), and the curative effect and prognosis.
  
  
  METHODS
  A retrospective study was conducted in nine cases with AML with t(16;21) (p11;q22) from January, 2009 to December, 2014 in People's Hospital of Peking University.
  
  
  RESULTS
  Of 1 372 AML patients, 9 cases with t(16;21) (p11;q22), 4 males and 5 females, were identified. According to the FAB classification, 1 case was classified as M1, 5 as M2, 1 as M4, 2 as M5. Three patients have morphological cavity at the time of diagnosis. Immunophenotypic features showed the positive CD117, CD13, CD33 and CD34, especially CD56. 5 cases were identified as complex karyotype abnormalities, besides from t (16;21) (p11;q22). All cases could be detected TLS/FUS-ERG fusion genes. 9 cases acquired complete remission (CR) after chemotherapy. 2 cases were only treated with chemotherapy and relapsed after 5 months and 16 months, and died at 10 months and 27 months after diagnosis. 7 of 9 cases accepted allogeneic hematopoietic stem cell transplantation (allo-HSCT) after chemotherapy, the median survival for 21 months (11-46 months). Summarized the 42 cases of adult AML with t (16;21) (p11;q22) from literature, 27 cases with chemotherapy alone, 15 cases underwent HSCT, the median survival for 10 (95% CI 1-17) months and 18(95% CI 2-76) months, respectively. The difference was statistically significant (P<0.001).
  
  
  CONCLUSIONS
  AML with t (16;21) (p11;q22) was rare, it has a special form and distinct immunophenotypic characteristics and poor prognosis, allo-HSCT could improve the prognosis and should be considered after CR.
authors.affiliation: Beijing University People's Hospital, Peking University Institute of Haematology, Beijing 100044, China.
authors.forename: M
authors.initials: M
authors.lastname: Ouyang
authors.forename: L P
authors.initials: LP
authors.lastname: Xu
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: H H
authors.initials: HH
authors.lastname: Zhu
authors.forename: Y Z
authors.initials: YZ
authors.lastname: Qin
authors.forename: Y Y
authors.initials: YY
authors.lastname: Lai
authors.forename: Y R
authors.initials: YR
authors.lastname: Liu
authors.forename: B
authors.initials: B
authors.lastname: Jiang
authors.forename: X J
authors.initials: XJ
authors.lastname: Huang
authors.forename: H
authors.initials: H
authors.lastname: Jiang
mesh_terms: D000328:Adult; D002885:Chromosomes, Human, Pair 16; D002891:Chromosomes, Human, Pair 21; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016130:Immunophenotyping; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy; D008297:Male; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D014178:Translocation, Genetic